- Ensysce Biosciences Inc (NASDAQ:ENSC) announced topline results from a human abuse potential (HAP) study for PF614.
- PF614 is a new class of analgesia, a Trypsin Activated Abuse-Protected (TAAP) oxycodone product.
- The HAP study was designed to test if known recreational drug users “liked” the product and is critical for new drugs in this class.
- The primary measure in this study, “drug liking,” is known to correlate with a drug’s potential for abuse.
- In the study, PF614 powder produced significantly lower peak “drug liking” when compared with intranasal crushed IR oxycodone.
- Furthermore, in the first-period analysis of initial impressions of each drug, a similarly strong difference was noted between PF614 (n=8) and crushed IR oxycodone (n=10), even with this smaller cohort of subjects.
- Related: Ensysce Biosciences, Quotient Partner To Work On Novel Opioid To Prevent Abuse and Overdose.
- Statistically significant differences in peak effects (Emax) between PF614 and crushed IR oxycodone intranasal were also demonstrated for the secondary endpoint of “take drug again,” where PF614 produced only 27% as high an Emax score as crushed oxycodone among recreational drug users.
- Price Action: ENSC shares are up 11.10% at $3.45 session on the last check Monday.
A Look At First Republic Bank’s Chart Following SVB Financial Collapse
First Republic Bank (NYSE: FRC) slid more than 6% in the premarket on Wednesday after four days of extreme volatility.
